CG Oncology, Inc. Common stock (CGON)
USD 28.45
(-2.8%)
USD 28.45
(-2.8%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 204 Thousand | 191 Thousand | 10.35 Million |
| Cost of Revenue | 45.75 Million | 15 Thousand | 10 Thousand |
| Gross Profit | -45.54 Million | 176 Thousand | 10.34 Million |
| Operating Expenses | 55.65 Million | 35.42 Million | 22.95 Million |
| Selling, General and Administrative Expenses | 9.9 Million | 6.39 Million | 4.63 Million |
| Research and Development Expenses | 45.75 Million | 29.02 Million | 18.31 Million |
| Other Expenses | - | -196 Thousand | 218 Thousand |
| Cost and Expenses | 55.65 Million | 35.43 Million | 22.96 Million |
| Operating Income | -55.44 Million | -35.24 Million | -12.6 Million |
| Interest Expense | - | 1000.00 | 451 Thousand |
| Income Tax Expense | - | - | - |
| Earnings before Tax | -48.6 Million | -35.44 Million | -12.83 Million |
| Net Income | -48.6 Million | -35.44 Million | -12.83 Million |
| Earnings Per Share Basic | -15.65 | -0.53 | -0.19 |
| Earnings Per Share Diluted | -15.65 | -0.53 | -0.19 |
| Weighted Average Shares Outstanding | 4.33 Million | 66.63 Million | 66.63 Million |
| Weighted Average Shares Outstanding (Diluted) | 4.33 Million | 66.63 Million | 66.63 Million |
| Gross Margin | -223.27 | 0.92 | 1.00 |
| EBIT Margin | -271.73 | -184.46 | -1.22 |
| Profit Margin | -238.27 | -185.57 | -1.24 |
| EBITDA | -55.43 Million | -35.23 Million | -12.37 Million |
| Earnings Before Tax Margin | -271.81 | -184.53 | -1.22 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 111 Thousand | 529 Thousand | 204 Thousand | 1000.00 | 9000.00 | - |
| Cost of Revenue | 7000.00 | 4000.00 | 17 Thousand | 4000.00 | - | 4000.00 |
| Gross Profit | 104 Thousand | 525 Thousand | 187 Thousand | -3000.00 | 9000.00 | -4000.00 |
| Operating Expenses | 25.95 Million | 22.99 Million | 55.63 Million | 18.92 Million | 14.47 Million | 12.32 Million |
| Selling, General and Administrative Expenses | 7.48 Million | 5.78 Million | - | 3.01 Million | 2.31 Million | 2.49 Million |
| Research and Development Expenses | 18.47 Million | 17.21 Million | - | 15.91 Million | 12.16 Million | 9.83 Million |
| Other Expenses | 8000.00 | -9000.00 | -62 Thousand | -4000.00 | -8000.00 | -58 Thousand |
| Cost and Expenses | 25.96 Million | 22.99 Million | 55.65 Million | 18.93 Million | 14.47 Million | 12.32 Million |
| Operating Income | -25.85 Million | -22.46 Million | -55.44 Million | -18.93 Million | -14.46 Million | -12.32 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | - | - | - | -2.26 Million | - |
| Earnings before Tax | -18.9 Million | -16.93 Million | -48.6 Million | -16.11 Million | -12.2 Million | -11.61 Million |
| Net Income | -18.9 Million | -16.93 Million | -48.6 Million | -16.11 Million | -12.2 Million | -11.61 Million |
| Earnings Per Share Basic | -0.28 | -0.36 | - | -0.24 | -0.18 | -0.17 |
| Earnings Per Share Diluted | -0.28 | -0.36 | - | -0.24 | -0.18 | -0.17 |
| Weighted Average Shares Outstanding | 66.64 Million | 47.06 Million | 66.63 Million | 66.63 Million | 66.63 Million | 66.63 Million |
| Weighted Average Shares Outstanding (Diluted) | 66.64 Million | 47.06 Million | 66.63 Million | 66.63 Million | 66.63 Million | 66.63 Million |
| Gross Margin | 0.94 | 0.99 | 0.92 | -3.00 | 1.00 | - |
| EBIT Margin | -232.85 | -42.47 | - | -18.92 Thousand | -1606.78 | - |
| Profit Margin | -170.29 | -32.01 | -238.27 | -16.11 Thousand | -1356.33 | - |
| EBITDA | -25.84 Million | -22.46 Million | - | -18.92 Million | -14.46 Million | -12.32 Million |
| Earnings Before Tax Margin | -232.91 | -42.47 | -271.81 | -18.93 Thousand | -1607.33 | - |
SELG
ALX
ARKO
2215
MDNDF
CLG